Cited by 135Adipose Tissue and MetabolismVirus-based gene therapy researchPeroxisome Proliferator-Activated Receptors

Molecular Therapy for Obesity and Diabetes Based on a Long-Term Increase in Hepatic Fatty-Acid Oxidation §Δ

Open access
Orellana-Gavaldà, Josep M., Herrero, Laura, Malandrino, Maria Ida, Pañeda, Astrid, Sol Rodríguez-Peña, Maria, Petry, Harald, Asins, Guillermina, Van Deventer, Sander +2 more·2011·Hepatology

Abstract

Obesity-induced insulin resistance is associated with both ectopic lipid deposition and chronic, low-grade adipose tissue inflammation. Despite their excess fat, obese individuals show lower fatty-acid oxidation (FAO) rates. This has raised the question of whether burning off the excess fat could improve the obese metabolic phenotype. Here we used human-safe nonimmunoreactive adeno-associated viruses (AAV) to mediate long-term hepatic gene transfer of carnitine palmitoyltransferase 1A (CPT1A), the key enzyme in fatty-acid β-oxidation, or its permanently active mutant form CPT1AM, to high-fat diet-treated and genetically obese mice. High-fat diet CPT1A- and, to a greater extent, CPT1AM-expressing mice showed an enhanced hepatic FAO which resulted in increased production of CO2, adenosine triphosphate, and ketone bodies. Notably, the increase in hepatic FAO not only reduced liver triacylglyceride content, inflammation, and reactive oxygen species levels but also systemically affected a decrease in epididymal adipose tissue weight and inflammation and improved insulin signaling in liver, adipose tissue, and muscle. Obesity-induced weight gain, increase in fasting blood glucose and insulin levels, and augmented expression of gluconeogenic genes were restored to normal only 3 months after AAV treatment. Thus, CPT1A- and, to a greater extent, CPT1AM-expressing mice were protected against obesity-induced weight gain, hepatic steatosis, diabetes, and obesity-induced insulin resistance. In addition, genetically obese db/db mice that expressed CPT1AM showed reduced glucose and insulin levels and liver steatosis. Conclusion : A chronic increase in liver FAO improves the obese metabolic phenotype, which indicates that AAV-mediated CPT1A expression could be a potential molecular therapy for obesity and diabetes. (Hepatology 2011)

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/hep.24140

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In these studies, enhanced mitochondrial FAO did not increase ROS derivatives or liver injury.

    “Furthermore, in these studies, enhanced mitochondrial FAO did not increase ROS derivatives or liver injury.”

    From Mitochondrial fatty acid oxidation in obesity (2013) · cites this paper as [130]

  • Potential mechanisms to explain the beneficial effects of targeting mitochondrial fatty acid oxidation could be the concomitant enhancement of hepatic ketone bodies, CO2, acid soluble products, ATP production, and endergonic processes (e.g., gluconeogenesis) seen in previous publications.

    “Potential mechanisms to explain the beneficial effects of targeting mitochondrial FAO could be the concomitant enhancement of hepatic ketone bodies, CO2, acid soluble products, ATP production, and endergonic processes (*e.g.,* gluconeogenesis) seen in previous publications ([38](#B38), [130](#B130), [158](#B158)).”

    From Mitochondrial fatty acid oxidation in obesity (2013) · cites this paper as [130]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

2 of the 40 references couldn’t be matched to a known paper.

Research works printed but not linked: 1

  1. Pessayre D, Fromenty B, Mansouri A. Mitochondrial injury in steato- hepatitis. Eur J Gastroenterol Hepatol 2004;16:1095-1105.

Cited by

Sorted by citations

Authors
Orellana-Gavaldà, J. M., Herrero, L., Malandrino, M. I., Pañeda, A., Sol Rodríguez-Peña, M., Petry, H., Asins, G., Van Deventer, S., Hegardt, F. G., & Serra, D.
Affiliations
Centro de Investigación Biomédica en Red (ES)
Corresponding author
Serra, Dolors
Venue
Hepatology
Published
2011-03
Volume
53
Issue
3
Pages
821-832
ISSN
0270-9139 (ISSN-L)
OpenAlex
W2134823147
Cited by
135
References
40
Citations by year
2026: 3 · 2025: 8 · 2024: 2 · 2023: 10 · 2022: 8 · 2021: 6 · 2020: 11 · 2019: 2 · 2018: 10 · 2017: 7 · 2016: 12 · 2015: 10 · 2014: 15 · 2013: 8 · 2012: 12
FWCI
6.71
Type
journal article
Language
en
Open access
Locations
  • Hepatology (publishedVersion)
  • PubMed (publishedVersion)
  • Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (submittedVersion, public-domain)
Funders
  • Universitat de Barcelona
  • Instituto de Salud Carlos III (CB06/03, CB06/03/0026)
Topics
  • Health Sciences › Medicine › Physiology › Adipose Tissue and Metabolism
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
Keywords
hepatic fatty acid oxidation, CPT1A, adeno-associated virus gene therapy, obesity, insulin resistance, type 2 diabetes, hepatic steatosis, high-fat diet, db/db mice, adipose tissue inflammation, gluconeogenesis, ketone bodies, molecular therapy
MeSH terms
Dependovirus, Animals, Carnitine O-Palmitoyltransferase, Diabetes Mellitus, Dietary Fats, Fatty Acids, Fatty Liver, Humans, Insulin Resistance, Liver, Male, Mice, Obese, Obesity, Oxidation-Reduction, Triglycerides, Genetic Therapy, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review